NCT05301608View on ClinicalTrials.gov

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

February 9, 2026

Study Completion Date

June 9, 2026

Conditions
Healthy
Interventions
DRUG

Psilocybin

The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 10 mg of psilocybin.

DRUG

Placebo

The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.

Trial Locations (1)

21224

RECRUITING

Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER